An observational study in Migraine, Episodic Migraine and Chronic Migraine, Headache, sponsored by Hospital Universitari Vall d'Hebron Research Institute. Recruiting at 26 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in Migraine Disorders with a site in Spain — 23 open to participants now, 35 under way, 15 of them phase 3. Migraine Disorders · Spain.
Among the 97 studies in Migraine Disorders with a site in Spain, this one is the 4th largest by planned enrollment of the 24 observational ones that give a count, is one of 10 that started in 2024, is one of 24 observational ones, reaches primary completion later than 9 of the 34 other live ones, and was the 91st registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →23 of the 97 studies in Migraine Disorders with a site in Spain are open now. Recruiting first, the newest first:
University of Seville · Sites in Spain
Ages 18–65
Pfizer · Sites in Spain, United States, Argentina and 12 more countries
Ages 18–45 · Women only
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages 18–45
Hospital Clínico Universitario de Valladolid · Sites in Spain
Ages 18+
H. Lundbeck A/S · Sites in Spain, United States, Argentina and 8 more countries
Ages 6–17
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 138 across 332 observational studies indexed under Migraine Disorders.
Median enrollment 512 across the 73 interventional studies, 231 across the 24 observational. Of the 57 that completed or were terminated, 32 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 97 have an industry lead sponsor. The 10 most frequent:
Hospital Universitari Vall d'Hebron Research Institute is the lead sponsor of 276 studies on the registry; 63 are open to participants now.
Hospital Universitari Vall d'Hebron Research Institute has 4 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
9 of the studies in Migraine Disorders with a site in Spain that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 97 studies in Migraine Disorders with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
It is a 2-year, multicenter observational study. Patients who meet reimbursement criteria according to local regulations and willing to participate in the study will be included. Monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) will be started and baseline assessment will be conducted. There will be visits every 6 months to assess effectiveness, side-effects, PROMs, and elegibility to continue with the study drug. The observation of patients will last 2 years.
Episodic and chronic migraine patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Migraine patients who initiate a CGRP-targeted treatment
Drug: CGRP antibody or gepant
Patients will start anti-CGRP or its receptor antibody or gepants
Change in Monthly Headache Days and Monthly Migraine Days
Time frame: Through study completion, an average of 2 years
HIT-6
Change in HIT-6 (Headache Impact Test) scale, to assess migraine impact.
Time frame: Through study completion, an average of 2 years
MIDAS
Change in MIDAS (Migraine Disability Assessment Scale) scale, to assess disability attributed to migraine.
Time frame: Through study completion, an average of 2 years
PGIC
PGIC (Patien Global Impression of Change) scale will be used to assess impression of change in migraine patients.
Time frame: Through study completion, an average of 2 years.
BAI
Change in BAI (Beck Anxiety Inventory) scale, to assess anxiety in migraine patients.
Time frame: Through study completion, an average of 2 years.
BDI-II
Change in BDI-II (Beck's Depression Inventory, 2nd version) scale, to assess depression in migraine patients.
Time frame: Through study completion, an average of 2 years.
MSQ Version 2.1
Changes in MSQ (Migraine-Specific Quality-of-Life) Version 2.1 scale, to assess patient's quality of life.
Time frame: Through study completion, an average of 2 years.
WPAI
Changes in WPAI (Work Productivity and Activity Impairment) questionnaire, to assess how migraine impacts in work and productivity in migraine patients.
Time frame: Through study completion, an average of 2 years.
ISI
Changes in ISI (Insomnia Severity Index) scale to assess insomnia in migraine patients.
Time frame: Through study completion, an average of 2 years.
ASC-12
Changes in ASC-12 (Allodynia Symptom Checklist) scale, to assess allodynia in migraine patients.
Time frame: Through study completion, an average of 2 years.
m-TOQ
m-TOQ (Migraine Treatment Optimization Questionnaire) scale will be used to assess the effectiveness of migraine treatment.
Time frame: Through study completion, an average of 2 years.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jan 2026, 24 months after the start.
Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's planned 24 months is below that.
Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitari Vall d'Hebron Research Institute →